Par Pharmaceutical Companies Inc.
300 Tice Boulevard
Woodcliff Lake,
NJ 07677
Phone: 201-802-4000
Web Site: http://www.parpharm.com
| REUTERS ABRIDGED BUSINESS SUMMARY | |
| Par Pharmaceutical Companies, Inc., through its subsidiary, Par Pharmaceutical, Inc. develops, manufactures, and distributes generic and branded pharmaceuticals drugs in the United States. Its principal generic products include Metoprolol succinate ER, Fluticasone, Meclizine Hydrochloride, Cabergoline, Sumatriptan succinate injection, Propranolol HCl ER, amoxicillin products, Dronabinol, Ibuprofen Rx, Megestrol oral suspension, Methimazole, Fluoxetine, Lovastatin, Tramadol HCl and acetaminophen tablets, Ranitidine HCl Syrup, Quinapril, and Cefprozil. The company offers its drugs in the solid oral dosage form, such as tablets, caplets, and two-piece hard-shell capsules, as well as oral suspension products and certain products in the semi-solid form of a cream. It markets its products to wholesalers, drug store chains, supermarket chains, mass merchandisers, distributors, managed health care organizations, mail order accounts, drug distributors, clinics, and government agencies. The companys brand products include Megace ES drugs for the treatment of anorexia, cachexia, or any unexplained significant weight loss in patients with a diagnosis of AIDS; and NanoCrystal Dispersion for megestrol acetate oral suspension. It has a joint venture with Rhodes Technology to research, develop, commercialize, and market pharmaceutical preparations for human therapy; a license and commercialization agreement with Intellipharmaceutics Corp. for the development of Dexmethylphenidate XR; and a development and supply agreement with Cipla Limited for the development of one generic product. The company has a collaboration agreement with Actavis Group for the development of 4 extended release generic products, such as Nifedipine XR, Methylphenidate LA, Zolpidem CR, and Alfuzosin. Par Pharmaceutical Companies, Inc. was founded in 1978 and is based in Woodcliff Lake, New Jersey. |
|
| Key Statistics | More from Reuters
Expanded Business Description |
| |
| REUTERS ABRIDGED FINANCIAL SUMMARY | |
| | Pay | Exercised | Mr. Patrick G. LePore , 55
Chairman, Chief Exec. Officer, Pres, Member of Corp. Devel. Review Committee, Chairman of Kali Laboratories Inc, Chief Exec. Officer of Kali Laboratories Inc and Pres of Kali Laboratories Inc |
$
800.00K |
$
0 | Mr. John A. MacPhee , 42
Exec. VP and Pres of Strativa Pharmaceuticals Division |
$
350.00K |
$
0 | Mr. Paul V. Campanelli , 48
Exec. VP and Pres of Generics Division |
$
350.00K |
$
0 | Mr. Thomas J. Haughey , 46
Chief Admin. Officer, Exec. VP, Sec., Gen. Counsel, Sec. of Kali Laboratories Inc and Gen. Counsel of Kali Laboratories Inc |
$
350.00K |
$
0 | Mr. Lawrence A. Kenyon CPA, 44
Chief Financial Officer and Exec. VP |
N/A
| N/A |
|
|
|
Dollar amounts are as of
31-Dec-08
and compensation values are for the last fiscal
year ending on that date. "Pay" is salary, bonuses, etc. "Exercised" is the value of
options exercised during the fiscal year.
| |
|
Help
Profile
Reuters offers more in-depth
